Study of BHV-1300 in Graves' Disease
ConditionGraves Disease
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBiohaven Therapeutics Ltd.
About this trial
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Eligibility criteria
Qualifiers
None
Disqualifiers
History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.
History of treatment with radioactive iodine or thyroid surgery.
Trial design
Treatments tested in this trial
- BHV-1300
Treatment groups
15 Participants
are divided into 1 treatment groupLocations
17Australia
Site-0043065, Fitzroy Australia
Site-0012289, Kotara Australia
Site-0033128, Melbourne Australia
Site-0105046, Oaklands Park Australia
Sponsors and collaborators
Biohaven Therapeutics Ltd.
Lead sponsor
Source ClinicalTrials.gov